Inozyme Pharma, Inc. (INZY)
- Previous Close
4.3300 - Open
4.3600 - Bid 4.4300 x 100
- Ask 4.4700 x 200
- Day's Range
4.2300 - 4.5050 - 52 Week Range
2.6890 - 7.7950 - Volume
504,042 - Avg. Volume
688,317 - Market Cap (intraday)
274.268M - Beta (5Y Monthly) 1.37
- PE Ratio (TTM)
-- - EPS (TTM)
-1.3700 - Earnings Date May 7, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
20.33
Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
www.inozyme.comRecent News: INZY
Performance Overview: INZY
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: INZY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: INZY
Valuation Measures
Market Cap
274.27M
Enterprise Value
132.27M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.95
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-1.97
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-27.81%
Return on Equity (ttm)
-54.98%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-71.17M
Diluted EPS (ttm)
-1.3700
Balance Sheet and Cash Flow
Total Cash (mrq)
188.59M
Total Debt/Equity (mrq)
33.17%
Levered Free Cash Flow (ttm)
-46.05M